Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RXRX · as of Sep 30, 2025
Ownership Breakdown
348
Institutional Holders
▼ 9 vs Q2
$1.59B
Total Inst. Value
▲ $15.66M vs Q2
447.19M
Shares Outstanding
freeFloat 77.90%
324.90M
13F Shares Held
▲ 14.64M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RXRX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 39.78M | 9.53% | 9.53% | $194.13B | Nov 7, 2025 | ▲ 3.71M |
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 33.55M | 8.04% | 8.04% | $163.70B | Nov 12, 2025 | ▲ 556.9K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 31.74M | 7.60% | 7.60% | $154.89B | Nov 12, 2025 | ▲ 3.37M |
BAILLIE GIFFORD & CO biological products, (no diagnostic substances) | 23.98M | 5.75% | 5.75% | $117.02B | Oct 31, 2025 | ▼ 195.1K |
STATE STREET CORP biological products, (no diagnostic substances) | 18.27M | 4.38% | 4.38% | $89.15B | Nov 14, 2025 | ▲ 7.09M |
SOFTBANK GROUP CORP. biological products, (no diagnostic substances) | 14.67M | 3.51% | 3.51% | $71.58B | Nov 14, 2025 | — held |
KINNEVIK AB (PUBL) biological products, (no diagnostic substances) | 13.43M | 3.22% | 3.22% | $65.56B | Nov 4, 2025 | — held |
MUBADALA INVESTMENT CO PJSC biological products, (no diagnostic substances) | 12.99M | 3.11% | 3.11% | $63.37B | Nov 14, 2025 | — held |
MIC CAPITAL MANAGEMENT UK LLP biological products, (no diagnostic substances) | 9.64M | 2.31% | 2.31% | $47.06B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 9.62M | 2.31% | 2.31% | $46.97B | Nov 12, 2025 | ▲ 1.85M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+27.64M shares2
New Positions
first time holders12
Decreased
−8.49M shares0
Sold Out
fully exitedNet shares change (top 50)
+19.15M
+27.64M / −8.49M
Net new holders
+14
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RXRX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
21
Sell transactions
0.33
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Gibson Christopher director | Jun 5, 2026 | C-Conversion | 40,000 | — | — | 4.26M | Form 4 ↗ |
Gibson Christopher director | Jun 5, 2026 | C-Conversion | 40,000 | — | — | 923.7K | Form 4 ↗ |
Gibson Christopher director | Jun 5, 2026 | Sale | 40,000 | $3.62 | $144.8K | 883.7K | Form 4 ↗ |
Khan Najat CEO and President | Jun 5, 2026 | Sale | 23,588 | $3.58 | $84.5K | 2.18M | Form 4 ↗ |
Bumpus Namandje director | Jun 3, 2026 | Sale | 4,386 | $3.54 | $15.5K | 43.2K | Form 4 ↗ |
Borgeson Blake director | Jun 2, 2026 | Sale | 30,000 | $3.68 | $110.4K | 6.17M | Form 4 ↗ |
Gibson Christopher director | May 22, 2026 | C-Conversion | 40,000 | — | — | 4.30M | Form 4 ↗ |
Gibson Christopher director | May 22, 2026 | C-Conversion | 40,000 | — | — | 923.7K | Form 4 ↗ |
Gibson Christopher director | May 22, 2026 | Sale | 40,000 | $3.08 | $123.2K | 883.7K | Form 4 ↗ |
Hallett David Chief Scientific Officer | May 15, 2026 | Tax Withhold | 26,657 | $3.04 | $81.0K | 1.07M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Recursion Pharmaceuticals, Inc. (RXRX) is primarily owned by institutional investors, who hold approximately 72.7% of total shares outstanding. Company insiders own approximately 22.10%, while retail and public investors account for the remaining 5.25%.
The largest institutional shareholder of Recursion Pharmaceuticals, Inc. is VANGUARD GROUP INC, holding approximately 39.78 million shares — equal to 9.53% of outstanding shares — as of September 30, 2025.
A total of 348 institutional investors currently hold RXRX stock, with a combined institutional value of approximately $1.59 billion as of the most recent 13F filing period.
Frequently asked questions
RXRX ownershipRecursion Pharmaceuticals, Inc. (RXRX) is primarily owned by institutional investors, who hold approximately 72.7% of shares. The largest shareholder is VANGUARD GROUP INC with a 9.53% stake. Company insiders hold 22.10%. Data sourced from SEC Form 13F as of September 30, 2025.